" />
Programmed cell death ligand 1 by clone 22C3:PrThr:Pt:Tiss:Ord:Immune stain - CISMeF
Programmed cell death ligand 1 by clone 22C3:PrThr:Pt:Tiss:Ord:Immune stainLOINC code
Preferred Label : Programmed cell death ligand 1 by clone 22C3:PrThr:Pt:Tiss:Ord:Immune stain;
LOINC status : ACTIVE;
LOINC display name : PD-L1 by clone 22C3 Immune stain Ql (Tiss);
LOINC long common name : PD-L1 by clone 22C3 [Presence] in Tissue by Immune stain;
LOINC short name : PD-L1 by 22C3 Tiss Ql ImStn;
LOINC description : This term should be used to report the presence of PD-L1 (CD274) protein expression
in tumor cells as determined by immune staining with anti-PD-L1 clone 22C3. Patients
with certain cancers, such as non-small cell lung cancer (NSCLC), whose tumors are
positive for PD-L1 by 22C3 are eligible for anti-programmed death 1 (PD-1) receptor
antibody therapy with pembrolizumab, which effectively prevents the binding of PD-L1
to PD-1. The percentage of viable tumor cells that show partial or complete PD-L1
membrane staining is reported using [LOINC: 83053-9]. A tumor with 50% staining by
22C3 is considered PD-L1 negative, and 50% is considered PD-L1 positive. This term
was created for, but is not limited in use to, the Dako PD-L1 22C3 pharmDx test kit,
which, as of November 2016, is FDA-approved as a companion diagnostic to assess whether
patients with specific cancers are eligible for pembrolizumab therapy.;
Has component